Mezzion Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Mezzion Pharmaceuticals is a rare disease company singularly focused on addressing the unmet medical needs of the Fontan patient community. Its primary asset is udenafil (JURVIGO®), a PDE5 inhibitor currently in a confirmatory Phase 3 trial (FUEL-2) for adolescents aged 12-18 with Fontan circulation, following a prior positive Phase 3 study (FUEL). The company is led by a founder-CEO with a financial background and a President/COO with deep expertise in PDE5 inhibitor development, positioning it to potentially bring the first FDA-approved therapy to this specific orphan indication. Mezzion operates as a private, clinical-stage biotech with a clear, patient-centric mission.

CardiovascularRare DiseasesCongenital Heart Disease

Technology Platform

Focused application and clinical development of PDE5 inhibitor pharmacology for the unique hemodynamics of Fontan circulation.

Opportunities

Mezzion has a first-mover opportunity to secure FDA approval for the first therapy specifically indicated for Fontan circulation, addressing a profound unmet need in a defined orphan disease population.

Success would grant it a monopoly position in a concentrated market, enabling premium pricing and high penetration within specialized pediatric cardiology centers.

Risk Factors

The company faces high binary risk on the outcome of its single confirmatory Phase 3 trial (FUEL-2).

Its entire value is tied to one asset for a very small patient population, creating vulnerability to clinical failure, regulatory hurdles, and future competition.

As a pre-revenue company, it also faces commercialization execution risk.

Competitive Landscape

There are currently no FDA-approved pharmaceutical therapies specifically for Fontan circulation, giving Mezzion a clear first-mover advantage. Competition may arise from other companies or academic groups investigating repurposed or novel therapies for Fontan complications, but the highly specialized nature of the disease presents a significant barrier to entry.

More companies in Small Molecule Drugs →More companies in United States →